ABSTRACT… Introduction: Chronic Hepatitis C (CHC) is a leading health issue for Pakistan. Other than the late complications of chronic liver disease, such as cirrhosis and hepatocellular carcinoma, a high frequency of anxiety and mood-disorder related symptoms has been described. Objective: To evaluate the morbidity Chronic Hepatitis C causes in the form of anxiety and depression in the affected individuals. Study Design: Observational, cross-sectional study. Setting: Medical Outdoor in Ibn-e-Sina Hospital, Multan. Period: 1 st October 2014 to 1 st March 2015. Methodology: In patients presenting with Chronic Hepatitis C and evaluated them for the presence of anxiety and depression using Hospital Anxiety and Depression Score. We found high prevalence of anxiety (36.6%) and Depression (29.2%) in the study population. The study population consisted of 281 patients with CHC (175 males---62.3% and 106 females-----37.7 %, mean age 39.3 ± 11.3). Results: Out of 281 patients, 94 (33.4%) were in the age group from 16-30 years, 104 (37%) in the age group 31-45 years whereas 68 (24.2%) were from the age group 40-60 years. Patients with were 103 (36.6%), while 178 patients were normal. Patients with depression were 82 (29.2%). Conclusion: Chronic Hepatitis C is associated with high percentage of anxiety and depression in the affected individuals and adds to the morbidity of the disease.
INTRODUCTION
Chronic hepatitis C (CHC) is a leading cause of health in Pakistan. Other than the late complicationsof chronic liver disease, such as cirrhosis and hepatocellular carcinoma, elevated frequency of anxiety -and mood-disorder related symptoms has been described.
1,2 Chronic hepatitis C (CHC) patients perform relatively poorly as compared to controls, in health-related quality of life indicators and this trend has been shown to improvewhen Sustained Viral Response (SVR) is achieved with interferon therapy. 3 The colossal prevalence of anxiety-and mood-disorder related symptoms has been described to be associated with a) the patient's awareness of the diagnosis and prognosis
4
, b) side effects induced by treatment with interferon (IFN)-alpha 5 and c) past or present substance abuse. However, Forton et al have hypothesized the straight outcome of HCV on brain neurocognitive function. 6 Evaluation for psychiatric symptoms in hepatitis is significant since they have poor effect upon the course of disease. Psychiatric problems in the patients with hepatitis may be responsible for functional impairment, reduced treatment compliance, and reduced quality of life.
7, 8 Successful medical treatment, consequently, requires detection and management of depression, anxiety and other psychiatric issues before and during the treatment.
9
Prospective studies designed to study the real effect of anxiety-and mood-disorders through clinical psychiatric tools, the prevalence rates of 25-28% for depressive disorders, and rates of 18-28% for anxiety disorders.Individuals with non-alcoholic fatty liver disease (NAFLD) and HCV had a higher prevalence of depression than HBV patients and general population. In addition, treatment of Chronic Hepatitis C which until recent past consisted of Interferon and Ribavirin has been observed to induce anxiety Though frequency of depression has been studied in Pakistani population, the prevalence of anxiety specificallyin patients with Chronic Hepatitis C by using the validated clinical tools has not been studied in Pakistani population yet. To study the effects of only Hepatitis C Virus (HCV) on the anxiety-and mood-disorder prevalence spectrum, it is important to rule out all other medical confounding factors.
METHODS
This cross-sectional and observational study was carried out at the Medical Outdoor in Ibn-eSina Hospital, Multan and included 281 patients of chronic hepatitis C from 1st October 2014 to 1 st March 2015, (175 males---62.3% and 106 females -37.7 %, mean age 39.3±11.3). The exclusion criteria included previous treatment with IFN-alpha, co-infection with HCV and HBV, HCV andHIV co-infection, cocaine, heroin and/or alcohol addiction, diagnosis of any malignancy, advanced chronic diseases like COPD, CKD and/or CCFand decompensated cirrhosis. All the patients participating in the study gave their informed consent. The diagnosis of Chronic Hepatitis C was made by the presence of PCR for HCV RNA and the evidence of liver damage by biochemical (ALT) or radiological (liver USG) or tissue elastography (Fibroscan) who have not undergone HCV therapy (interferon or Sofosbuvirl).Depression and Anxiety were assessed by Hospital Anxiety and Depression Scale (HADS) questionnaire. This questionnaire included 14 questions. Each question had 4choices (0 -3). Maximum score of depression in thisquestionnaire was 21.We labelled patients as having Anxiety and Depression who had HADS-A and HADS-D score 8 or more and those having score 7 or less as Normal. As HADS-A and HADS-D score of 08 has been found to be an optimal balance between the sensitivity and the specificity of the HADS score.
14 The study employed a translated and validated Urdu version of this scale. 15 The patients, who were not able to fill in the questionnaire themselves, were helped by a team of young doctors who were trained to administer questionnaire and assess the answers. The data was analyzed through SPSS-20. Data was expressed in the form of frequencies and percentages. 
RESULTS

Age range in
DISCUSSION
The present study found high prevalence rate of 27% of anxiety and depression. It is also comparable with the reported rates of 25-28% found using psychiatric diagnostic tools (5-7)and less than the rate of 37.8% found in the Pakistani study using the HADS.
15
The frequency of anxiety is 37.7% higher than the international literature where the rates of 18-28% have been reported. [5] [6] [7] Ours was first study in Pakistan where the clinical anxiety was measured along with depression using HADS. Both Anxiety and Depression were slightly more frequent in female patients as was noted by Carta et al 9 and Golden et al. 10 Our patients were markedly early in the staging of the disease (patients with
